NewsBenzingaGuggenheim mejora la calificación de Editas Medicine a Comprar, anuncia un precio objetivo de $5 Guggenheim mejora la calificación de Editas Medicine a Comprar, anuncia un precio objetivo de $5 Benzinga 2026.09.23 12:29 (GMT+0) Open on Benzinga Other news Yum China Stock Is Satistically Terrible. Here’s What Wall Street Isn’t Telling You. Is DaVita Stock Underperforming the S&P 500? The Clorox Company Stock: Is CLX Underperforming the Consumer Staples Sector? Trump's Strategy Stock Trades Draw Scrutiny as MSTR Surges 83% Microsoft Is Cutting 268 Xbox Roles as Activision Takes Over Halo. This Is a Simple Restructuring, Not a Broader Panic Signal for MSFT Stock. Nvidia Partner IonQ Sparks a Quantum Computing Stock Rally — Here’s One Way to Invest.
Microsoft Is Cutting 268 Xbox Roles as Activision Takes Over Halo. This Is a Simple Restructuring, Not a Broader Panic Signal for MSFT Stock.
